thiazide to high-dose tolvaptan is expected to attenuate aquaretic events and to prevent the discontinuation of treatment with tolvaptan. Moreover, even among the patients with ADPKD who tolerate tolvaptan, the addition of trichlormethiazide to the treatment improved several HRQOL subscales, including ...
Autosomal Dominant Polycystic Kidney Disease (ADPKD) is one of the most common monogenic disorders, characterized by the progressive formation of fluid-filled cysts. Tolvaptan is an approved drug for ADPKD patients, but is also associated with multiple side effects. The peroxisome proliferator-activator...